4月7日晚(wan)間(jian)，爾康(kang)制藥(yao)(yao)(yao)(300267)公(gong)(gong)(gong)告，近日，公(gong)(gong)(gong)司(si)從國家藥(yao)(yao)(yao)品(pin)監督管理(li)局藥(yao)(yao)(yao)品(pin)審評中心(CDE)“原(yuan)(yuan)料藥(yao)(yao)(yao)、藥(yao)(yao)(yao)用輔(fu)料和藥(yao)(yao)(yao)包材登記信息(xi)公(gong)(gong)(gong)示”平臺查詢獲悉，全資子公(gong)(gong)(gong)司(si)湖(hu)南(nan)湘易康(kang)制藥(yao)(yao)(yao)有限(xian)公(gong)(gong)(gong)司(si)提交(jiao)的“磷酸(suan)哌嗪”、“雙嘧達莫”、“磷酸(suan)苯丙哌林”原(yuan)(yuan)料藥(yao)(yao)(yao)(受(shou)理(li)號：CYHT1600561、CYHT1600562、CYHT1600546)通過了CDE審批。